
.webp)
.webp)
.webp)
.webp)
The Mississippi Board of Pharmacy recently announced a new Medical Device Establishment license in the state.
The change was made in the last legislative session, and information was included in the board’s January 2026 quarterly newsletter and within a separate email announcement distributed on March 3rd, 2026.
The announcement outlines a change to the definition of a “device,” which changes how companies are regulated within the state.
The previous definition: (g) “Device” means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component part or accessory which is required under federal or state law to be prescribed by a practitioner and dispensed by a pharmacist.
The new definition: (g) "Device" means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component part or accessory which is required under federal or state law to be prescribed by a practitioner.
LighthouseAI has confirmed this new requirement and the following details with a member of the Mississippi Board of Pharmacy.
If you didn't already know about this new Mississippi requirement, you're not alone.
However, missing requirements like this can mean fines, suspended shipments, or disciplinary actions.
LighthouseAI monitors all US states and sends automated alerts tailored to your product portfolio and facility operations. No noise. No manual research. Just the updates that matter to you, with enough time to act.
What you don't know can hurt you. LighthouseAI will make sure you know.
Contact us to learn more here: Contact LighthouseAI
If you have any questions about this latest licensing regulatory requirement, please contact us at hello@lighthouseai.com.


About the Author:
Sandy Cater is a Senior Manager of Research and Development at LighthouseAI with over a decade of experience in the pharmaceutical life sciences industry. She specializes in regulatory compliance research and analysis across the pharmaceutical sector. Sandy focuses on developing high-quality compliance insights and research methodologies that help organizations navigate complex regulatory frameworks and maintain compliance throughout the pharmaceutical supply chain.